Structure Therapeutics
Structure Therapeutics develops oral small-molecule drugs that target GLP-1, a gut hormone that regulates appetite and blood sugar, placing it among the makers of the core active compounds in the metabolic-disease field.
Checked against the company's own business description in its latest annual filing.
Latest disclosed
10-Q filed 2026-08-06 · period ending 2026-06-30
Pieces naming this company
None yet.
No price is shown: the Index is a map of what each company sells and where it sits, not a quote board.